A double-blind, single-dose, crossover comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine versus placebo

Suppression of histamine-induced wheal and flare response for 24 h in

J. A. Grant, L. Danielson, J. P. Rihoux, C. DeVos

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

Background: New H1-antagonists have become available, but there has been no comparison of their potency for inhibiting histamine in the skin. Methods: Cetirizine 10 mg, ebastine 10 mg, epinastine 20 mg, fexofenadine 60 mg, terfenadine 60 mg, loratadine 10 mg, or placebo was given to 14 healthy male volunteers in a double-blind, crossover randomized manner. Inhibition of the wheal and flare response to epicutaneous histamine phosphate (100 mg/ml) challenge was measured at 0, 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 h after doses. Results: Epinastine inhibited the wheal and flare after 30 min. Cetirizine commenced acting at 1 h and was superior to other treatments. Ebastine was no better than placebo until 4 h, but was efficacious thereafter until 24 h. Terfenadine induced potent inhibition after 1 h and was superior to its metabolite fexofenadine. Loratadine was the least potent inhibitor. Inhibition of the flare response paralleled the patterns seen for wheals. The rank order for area under the curve (0-24 h) was cetirizine, epinastine, terfenadine, ebastine, fexofenadine, loratadine, and placebo. Conclusions: The inhibition of histamine effects in the skin may be useful in predicting the clinical utility of newly introduced antihistamines in treating allergic disorders.

Original languageEnglish (US)
Pages (from-to)700-707
Number of pages8
JournalAllergy: European Journal of Allergy and Clinical Immunology
Volume54
Issue number7
DOIs
StatePublished - 1999

Fingerprint

fexofenadine
Loratadine
Cetirizine
Terfenadine
Histamine
Placebos
Histamine Agents
Skin
Histamine Antagonists
Area Under Curve
Healthy Volunteers
epinastine
ebastine

Keywords

  • Cetirizine
  • Ebastine
  • Epinastine
  • Fexofenadine
  • Histamine
  • Histamine H- antagonists
  • Loratadine
  • Skin tests
  • Terfenadine

ASJC Scopus subject areas

  • Immunology

Cite this

@article{8c72fcebacf44c4a8d74067ce727fbde,
title = "A double-blind, single-dose, crossover comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine versus placebo: Suppression of histamine-induced wheal and flare response for 24 h in",
abstract = "Background: New H1-antagonists have become available, but there has been no comparison of their potency for inhibiting histamine in the skin. Methods: Cetirizine 10 mg, ebastine 10 mg, epinastine 20 mg, fexofenadine 60 mg, terfenadine 60 mg, loratadine 10 mg, or placebo was given to 14 healthy male volunteers in a double-blind, crossover randomized manner. Inhibition of the wheal and flare response to epicutaneous histamine phosphate (100 mg/ml) challenge was measured at 0, 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 h after doses. Results: Epinastine inhibited the wheal and flare after 30 min. Cetirizine commenced acting at 1 h and was superior to other treatments. Ebastine was no better than placebo until 4 h, but was efficacious thereafter until 24 h. Terfenadine induced potent inhibition after 1 h and was superior to its metabolite fexofenadine. Loratadine was the least potent inhibitor. Inhibition of the flare response paralleled the patterns seen for wheals. The rank order for area under the curve (0-24 h) was cetirizine, epinastine, terfenadine, ebastine, fexofenadine, loratadine, and placebo. Conclusions: The inhibition of histamine effects in the skin may be useful in predicting the clinical utility of newly introduced antihistamines in treating allergic disorders.",
keywords = "Cetirizine, Ebastine, Epinastine, Fexofenadine, Histamine, Histamine H- antagonists, Loratadine, Skin tests, Terfenadine",
author = "Grant, {J. A.} and L. Danielson and Rihoux, {J. P.} and C. DeVos",
year = "1999",
doi = "10.1034/j.1398-9995.1999.00032.x",
language = "English (US)",
volume = "54",
pages = "700--707",
journal = "Allergy: European Journal of Allergy and Clinical Immunology",
issn = "0105-4538",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - A double-blind, single-dose, crossover comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine versus placebo

T2 - Suppression of histamine-induced wheal and flare response for 24 h in

AU - Grant, J. A.

AU - Danielson, L.

AU - Rihoux, J. P.

AU - DeVos, C.

PY - 1999

Y1 - 1999

N2 - Background: New H1-antagonists have become available, but there has been no comparison of their potency for inhibiting histamine in the skin. Methods: Cetirizine 10 mg, ebastine 10 mg, epinastine 20 mg, fexofenadine 60 mg, terfenadine 60 mg, loratadine 10 mg, or placebo was given to 14 healthy male volunteers in a double-blind, crossover randomized manner. Inhibition of the wheal and flare response to epicutaneous histamine phosphate (100 mg/ml) challenge was measured at 0, 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 h after doses. Results: Epinastine inhibited the wheal and flare after 30 min. Cetirizine commenced acting at 1 h and was superior to other treatments. Ebastine was no better than placebo until 4 h, but was efficacious thereafter until 24 h. Terfenadine induced potent inhibition after 1 h and was superior to its metabolite fexofenadine. Loratadine was the least potent inhibitor. Inhibition of the flare response paralleled the patterns seen for wheals. The rank order for area under the curve (0-24 h) was cetirizine, epinastine, terfenadine, ebastine, fexofenadine, loratadine, and placebo. Conclusions: The inhibition of histamine effects in the skin may be useful in predicting the clinical utility of newly introduced antihistamines in treating allergic disorders.

AB - Background: New H1-antagonists have become available, but there has been no comparison of their potency for inhibiting histamine in the skin. Methods: Cetirizine 10 mg, ebastine 10 mg, epinastine 20 mg, fexofenadine 60 mg, terfenadine 60 mg, loratadine 10 mg, or placebo was given to 14 healthy male volunteers in a double-blind, crossover randomized manner. Inhibition of the wheal and flare response to epicutaneous histamine phosphate (100 mg/ml) challenge was measured at 0, 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 h after doses. Results: Epinastine inhibited the wheal and flare after 30 min. Cetirizine commenced acting at 1 h and was superior to other treatments. Ebastine was no better than placebo until 4 h, but was efficacious thereafter until 24 h. Terfenadine induced potent inhibition after 1 h and was superior to its metabolite fexofenadine. Loratadine was the least potent inhibitor. Inhibition of the flare response paralleled the patterns seen for wheals. The rank order for area under the curve (0-24 h) was cetirizine, epinastine, terfenadine, ebastine, fexofenadine, loratadine, and placebo. Conclusions: The inhibition of histamine effects in the skin may be useful in predicting the clinical utility of newly introduced antihistamines in treating allergic disorders.

KW - Cetirizine

KW - Ebastine

KW - Epinastine

KW - Fexofenadine

KW - Histamine

KW - Histamine H- antagonists

KW - Loratadine

KW - Skin tests

KW - Terfenadine

UR - http://www.scopus.com/inward/record.url?scp=0032837646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032837646&partnerID=8YFLogxK

U2 - 10.1034/j.1398-9995.1999.00032.x

DO - 10.1034/j.1398-9995.1999.00032.x

M3 - Article

VL - 54

SP - 700

EP - 707

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

SN - 0105-4538

IS - 7

ER -